Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK5 | P34947 | 1/20 | 0.53 |
| ▸ | ATR | Q13535 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | SMYD2 | Q9NRG4 | 5/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2749708 | 0.93 | GRK5 (0.62) | GRK5ATRTP53MAP4K4 | |
| SCHEMBL2749322 | 0.85 | NAMPT (0.53) | MEN1KMT2A | |
| SCHEMBL2749016 | 0.84 | FYN (0.51) | GRK5TP53MAP4K4HPGDMAPT | |
| SCHEMBL2748906 | 0.83 | PRKD3 (0.62) | GRK5TP53MAP4K4HPGDMAPT | |
| SCHEMBL2749700 | 0.81 | ATR (0.52) | ATRMAP4K4HPGDFYN | |
| SCHEMBL2750800 | 0.81 | PRKD3 (0.54) | GRK5TP53MAP4K4MEN1HPGD | |
| SCHEMBL2748849 | 0.81 | CDK8 (0.50) | TP53MAP4K4MEN1HPGDKMT2A | |
| SCHEMBL2749406 | 0.81 | ATR (0.58) | GRK5ATRTP53MAP4K4HPGD | |
| SCHEMBL2750571 | 0.81 | ATR (0.51) | ATRMAP4K4MEN1HPGDKMT2A | |
| SCHEMBL2747422 | 0.79 | MAP4K4 (0.58) | ATRMAP4K4MEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178668-B2 | 2-aminopyridine kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | GRK5 317/4885ATR 347/4885TP53 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.